Giossi, Riccardo http://orcid.org/0000-0002-7352-9445
Mercenari, Martina
Filippi, Massimo
Zanetta, Chiara
Antozzi, Carlo Giuseppe
Brambilla, Laura
Confalonieri, Paolo
Crisafulli, Sebastiano Giuseppe
Tomas Roldan, Eugenia
Annovazzi, Pietro
Conti, Marta Zaffira
Barrilà, Caterina
Ronzoni, Marco
Grobberio, Monica
Negri, Attilio
Gustavsen, Stefan
Torri Clerici, Valentina
Article History
Received: 28 March 2024
Revised: 18 May 2024
Accepted: 22 May 2024
First Online: 7 June 2024
Declarations
:
: Dr. R. Giossi received support for congress participation from Mylan and acted as a consultant for Daiichi-Sankyo, outside this work. Prof. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Horizon, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Horizon, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Horizon, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Dr. C. Zanetta received compensation for speaking activities, and/or consulting services, from Alexion, Astrazeneca, Biogen, Bristol-Myers Squibb, Janssen, Merck, Novartis, Roche, Sanofi. Dr. C. Antozzi received funding for traveling from Teva, Merck and Biogen. Dr. L. Brambilla received honoraria for speaking from Novartis, Roche, Horizon, and for traveling from Sanofi-Genzyme, Merck-Serono, Novartis, Horizon and Roche; she acted as an Advisory Board member of Sanofi-Genzyme, Novartis and Merck-Serono and she is involved as principal investigator in clinical trials for Roche and Merck-Serono. Dr. P. Confalonieri has received honoraria for speaking or consultation fees from Novartis, Bristol Myers and Biogen, has received funding for travel to attend scientific events or speaker honoraria from Merck-Serono, Biogen Idec, Mylan and Roche. He has also received institutional research support from Merk-Serono, Novartis and Roche. He is also principal investigator in clinical trials for Novartis and Roche. Dr. S.G. Crisafulli received support for congress participation from Mylan, Merck-Serono, Novartis. He acted as an Advisory Board member for Novartis. Dr. P. Annovazzi received honoraria for lecturing and participation in advisory boards, and/or travel expenses for attending congresses and meetings from Alexion, Almirall, Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva and Viatris. Dr. C. Barrilà participated in improvements groups for Biogen, Sanofi, Novartis, and Merck. Dr. M. Ronzoni received honoraria for congress participation and/or advisory board from Alexion, Almirall, Biogen, Bristol Meyers Squibb, Horizon, Genzyme, Merck, Novartis, Roche, Sanofi, and Teva. Dr. S. Gustavsen has received support for congress participation from Merck and Sanofi. Dr. V. Torri Clerici acted as an Advisory Board member of Biogen Idec and Novartis, and received funding for travelling and honoraria for speaking or writing from Teva, Novartis, Genzyme, Almirall. She received support for research project by Almirall. Other authors have nothing to disclose.